| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The primary target of Acloproxalap is reactive aldehydes, which are toxic byproducts of lipid peroxidation and other oxidative stress pathways. As an aldehyde scavenger, it binds to and neutralizes these reactive species, preventing them from causing cellular damage. By targeting toxic aldehyde accumulation, Acloproxalap may help reduce inflammation and tissue damage in diseases where oxidative stress plays a role.
|
|---|---|
| ln Vitro |
In vitro, Acloproxalap functions as an aldehyde scavenger, binding to and neutralizing toxic aldehydes. Specific activity data, such as IC50 values, are not provided in the available sources. Its activity is characterized by its ability to reduce aldehyde levels in biochemical assays.
|
| ln Vivo |
Alloprosa (Compound I-6) (100 or 200 mg/kg, intraperitoneally or orally, daily, for 6 days) substantially reduces colon inflammation in female Swiss Webster mice with acute ulcerative colitis (UC) [1] .
In vivo, Acloproxalap is being investigated for its potential therapeutic applications in diseases involving toxic aldehyde accumulation. It may help inhibit tumor cell proliferation and induce cell death in the context of cancer treatment. Specific in vivo efficacy data are not provided in the available sources. |
| Enzyme Assay |
A cell-free assay for Acloproxalap would involve measuring its ability to scavenge aldehydes. In these assays, the compound is incubated with a reactive aldehyde (e.g., 4-hydroxynonenal or malondialdehyde), and the reduction in aldehyde levels is measured using HPLC or spectrophotometric methods. Specific protocols are not detailed.
|
| Cell Assay |
Cellular assays for Acloproxalap would typically involve assessing its ability to protect cells from aldehyde-induced damage. Cells are treated with the compound and exposed to toxic aldehydes, and markers of cell viability, oxidative stress, and inflammation are measured. Specific protocols are not detailed.
|
| Animal Protocol |
Animal/Disease Models: Female Swiss Webster mice with acute ulcerative colitis (UC) [1]
Doses: 100 mg/kg, 200 mg/kg Route of Administration: intraperitoneal (ip) injection of 100 mg/kg, po (oral gavage) of 200 mg/kg; Daily; 6-day Experimental Results: The weight loss of mice treated with intraperitoneal (ip) injection was Dramatically inhibited, while there was no significant difference between the po (oral gavage) group and the control group. Both Dramatically diminished colonic histopathological parameters. Animal/Disease Models: Male non-puppy beagle [2] Doses: 3 mg/kg Route of Administration: intravenous (iv) (iv)injection; Experimental Results: pharmacokinetic/PK/PK parameters of Alloprosa (Compound I-1) Parameters of Alloprosa ( Compound I-1) t1/2 1.82 h Tmax 0.518 h Clearance rate 12.2 mL/kg/min Steady-state volume 1385 mL/kg AUC0-t 4103 ng/mL*h AUC0-inf_obs 4137 ng/mL*h Animal/Disease Models: Male Non-puppy beagle dogs [2] Doses: 10 mg/kg Route of Administration: po (oral gavage); Experimental Results: pharmacokinetic/PK/PK parameters of Alloprosa (Compound I-1) Parameters of Alloprosa (Comp In vivo animal experiments for Acloproxalap are not described in the available sources. As an investigational compound, it could be evaluated in animal models of inflammatory diseases or cancer. However, no specific protocols or data are provided. |
| ADME/Pharmacokinetics |
Acloproxalap has a molecular formula of C12H14N2O and a molecular weight of approximately 202.25. Its IUPAC name is 2-(3-aminoquinolin-2-yl)propan-2-ol. Specific pharmacokinetic parameters are not provided in the available sources. The compound is an investigational agent.
|
| Toxicity/Toxicokinetics |
Toxicity data for Acloproxalap are not provided in the available sources. As a research compound, it is intended for research use only and not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
Acloproxalap (CAS: 1824609-67-7) is a quinoline-based aldehyde scavenger. It is also known as ADX-629. The compound is used in studies of diseases with toxic aldehyde accumulation, including inflammatory diseases of the eye and skin, respiratory diseases, and viral infection-related syndromes. Its molecular formula is C12H14N2O. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
C12H14N2O
|
|---|---|
| Molecular Weight |
202.25
|
| Exact Mass |
202.11
|
| CAS # |
1824609-67-7
|
| PubChem CID |
117758222
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
230
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1C(=CC2C=CC=CC=2N=1)N)(O)(C)C
|
| InChi Key |
NOFRQDXKZDAYGB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H14N2O/c1-12(2,15)11-9(13)7-8-5-3-4-6-10(8)14-11/h3-7,15H,13H2,1-2H3
|
| Chemical Name |
2-(3-aminoquinolin-2-yl)propan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~494.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9444 mL | 24.7219 mL | 49.4438 mL | |
| 5 mM | 0.9889 mL | 4.9444 mL | 9.8888 mL | |
| 10 mM | 0.4944 mL | 2.4722 mL | 4.9444 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
